Updates are available Correction dated 2022-10-26

Article History

Received: 22 January 2022

Accepted: 24 April 2022

First Online: 1 June 2022

Change Date: 28 August 2022

Change Type: Update

Change Details: Missing Open Access funding information has been added in the Funding Note.

Change Date: 26 October 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s10151-022-02714-w

Declarations

:

: Marco Daperno reports consulting fees from Bioclinica; honoraria from Janssen, Abbvie, Takeda, Pfizer, Roche; support for attending meetings from SOFAR, Chiesi, Takeda, Janssen, Abbvie, Mundifarma, Roche; Alessandro Armuzzi reports grants from Pfizer and Takeda; consulting fees from AbbVie, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda; honoraria from AbbVie, Amgen, Arena, Biogen, Bristol-Myers Squibb, Galapagos, Gilead, Janssen, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda; support for attending meetings from Abbvie, Janssen, Pfizer, Takeda; Antonio Rispo reports grants from AbbVie, MSD, Janssen, Takeda, Chiesi; consulting fees from AbbVie, MSD, Janssen, Takeda, Chiesi; honoraria from AbbVie, MSD, Janssen, Takeda, Chiesi; participation on a data safety monitoring board or advisory board for AbbVie, MSD, Janssen, Takeda, Chiesi. All other authors have no conflicts of interest to declare.

: Ethical approval for the study was granted by the institutional review board of Spedali Civili and University of Brescia (approval number NP4700, 22 April 2021). All patients (or the guardians of patients aged < 18 years) provided informed consent for the collection of their clinical data for medical purposes, and the institutional review board waived the need for further informed consent. The data were anonymized by each contributor before transmission.